Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug combinations) indicated ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopia ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously treated stage II, stage III, or stage IV ovarian ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants wi ... Read more >
